Our observation that administration of 24(S)-saringosterol as a preferential LXRβ activator does not induce hepatic steatosis is in line with the assumption that triglyceride accumulation in the liver is predominantly driven by LXRα activation [19]. Here, NR1H2 is linked to Hepatic steatosis.